| Returns | 1W : 1.2% , 1M : -0.2%,1Y : 71.2% |
| Peers & Returns | 1W | 1M | 1Y |
| INDOCO REMEDIES | 1.2% | -0.2% | 71.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.2% | -3.7% | 21% |
| DRREDDYS LABORATORIES | -0.7% | -1.7% | 84.4% |
| DIVIS LABORATORIES | -0.8% | -2.3% | 77.5% |
| CIPLA | -0.9% | -1.3% | 70.7% |
| PIRAMAL ENTERPRISES | 0.3% | 7.3% | -23.4% |
| LUPIN | -2.3% | -2.5% | 34.4% |
| AUROBINDO PHARMA | -2.2% | 0.3% | 64.2% |
| TORRENT PHARMACEUTICALS | 2.3% | 2.8% | 61.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
41.93 3.05 2.08 2.51 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
89% 75% 55% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.38 0.45 0.42 0.42 |
0.39 0.45 0.42 0.42 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
1.41% 45.2% 210.77% 219.07% |
9.18% 110% 8557.14% 690.37% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
